** Danaher DHR.N beat Wall Street estimates for first-quarter profit on Tuesday, and said it expects to incur additional tariff-related costs of about $350 million this year
** Median PT of brokerages covering the stock is $246.50, per data compiled by LSEG
ABLE TO NAVIGATE TOUGH ENVIRONMENT
** Leerink Partners ("outperform", PT:$230) says it sees DHR as the leader in the recurring revenue market of bioprocess tools
** William Blair ("outperform") says Danaher is well insulated from broader macro headwinds (e.g., weaker U.S. academic and government market, slowdown in biotech funding, tariffs)
** Evercore ISI ("outperform", PT:$230) says underlying order momentum and backlog build was a solid data point that suggests order patterns normalizing
** RBC Capital Markets ("outperform," PT:$250) says DHR's positive Q1 results provides a much-needed piece of good news for the sector
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.